Results(4745)
Postmarketing non-interventional safety study on medicinal products containing aromatase inhibitors, Anastrozol Actavis 1 mg, Exemestan Actavis 25 mg, Trozara 2,5 mg
Czechia
EU PAS number:
EUPAS11481
First published:
02/11/2015
Study
Planned
Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their Knowledge of XGEVA® Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw (20110102)
Denmark
Finland
France
Germany
Italy
Norway
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS5345
First published:
30/10/2015
Study
Finalised
Epidemiology (Rotterdam Study), Erasmus Medical Center (ErasmusMC)
Netherlands
First published:
29/10/2015
Institution
Outdated
Educational Institution
ENCePP partner
RISK OF CARDIOVASCULAR EVENTS IN PATIENTS USING TOCILIZUMAB AS COMPARED WITH OTHER BIOLOGICS IN MULTIPLE LARGE HEALTHCARE DATABASES (EUPAS11327)
United States
EU PAS number:
EUPAS11327
First published:
15/10/2015
Study
Planned
Characterizing the Management of Hypocalcemia Among Patients on Hemodialysis Receiving Cinacalcet Treated Within a Large US Dialysis Provider (20140132)
United States
EU PAS number:
EUPAS6210
First published:
07/10/2015
Study
Finalised
State of the Union: Current asthma morbidity in the UK
United Kingdom
EU PAS number:
EUPAS8740
First published:
26/08/2015
Study
Finalised
Postmarketing Requirement (PMR) Non-Interventional 2-armed Study to Evaluate the Safety of octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, with a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events (TEEs) (GAM5-28)
United States
EU PAS number:
EUPAS10738
First published:
20/08/2015
Study
Ongoing
Infant and childhood neurodevelopmental outcomes following prenatal exposure to selective serotonin reuptake inhibitors: overview and design of a Finnish Register-Based Study (FinESSI)
Finland
EU PAS number:
EUPAS10694
First published:
18/08/2015
Study
Ongoing
Increasing ICS Dose vs Add-on Therapy in Children with Asthma (Paediatric Asthma Step-up)
United Kingdom
EU PAS number:
EUPAS10483
First published:
31/07/2015
Study
Finalised
Centre de pharmaco-épidémiologie (Paris Pharmacoepidemiology Centre), Assistance Publique, Hôpitaux de Paris
France
First published:
22/07/2015
Institution
Outdated
Educational Institution
Hospital/Clinic/Other health care facility
ENCePP partner
AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF FIRST LINE METASTATIC COLORECTAL ADENOCARCINOMA (ACORN)
United Kingdom
EU PAS number:
EUPAS10344
First published:
21/07/2015
Study
Ongoing
Risk factors For Bone Pain among Neulasta® Users (20120320)
Australia
Austria
Belgium
Canada
France
Germany
Italy
Luxembourg
Mexico
Netherlands
Poland
Portugal
Russian Federation
Spain
Sweden
United Kingdom
United States
EU PAS number:
EUPAS5644
First published:
17/07/2015
Study
Finalised
A retrospective cohort study with chart review to assess the management of major bleeding events in NVAF patients treated with dabigatran etexilate
United States
EU PAS number:
EUPAS6568
First published:
17/06/2015
Study
Planned
Post-discharge Clinical and Economic Outcomes Among Patients with ACS Managed with PCI and treated with Prasugrel versus Ticagrelor (H7T-MC-B023)
United States
EU PAS number:
EUPAS9949
First published:
15/06/2015
Study
Finalised
Comparison Of Clinical Outcomes, Resource Utilisation, And Costs In Patients Hospitalized For ACS Managed With PCI And Receiving Prasugrel Or Ticagrelor (H7T-US-B019)
United States
EU PAS number:
EUPAS9938
First published:
11/06/2015
Study
Finalised
Risk factors of intussusception in children under the age of 1 year: retrospective case-control study
Germany
EU PAS number:
EUPAS9814
First published:
27/05/2015
Study
Planned
Effect of Cinacalcet Discontinuation on Biochemical Control for Medicare Beneficiaries with Part D Coverage Treated within a Large US Dialysis Provider (20130335)
United States
EU PAS number:
EUPAS5641
First published:
21/05/2015
Study
Finalised
A Registry in the European Union of Provenge Therapy in Men with Metastatic Castrate-Resistant Prostate Cancer (START)
Austria
Germany
Netherlands
United Kingdom
EU PAS number:
EUPAS8254
First published:
21/05/2015
Study
Planned
The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis
United States
EU PAS number:
EUPAS9771
First published:
20/05/2015
Study
Ongoing
ALTO, An international non-interventional registry on the quality of life of patients with grass pollen-induced Allergic Rhinitis Treated with Oralair®
Austria
Belgium
France
Germany
Italy
Netherlands
Russian Federation
Spain
Switzerland
EU PAS number:
EUPAS6076
First published:
18/05/2015
Study
Ongoing
Metabolic effects associated with ICS (inhaled corticosteroid) use in COPD (chronic obstructive pulmonary disease) patients with type II diabetes
United Kingdom
EU PAS number:
EUPAS6804
First published:
15/05/2015
Study
Finalised
A Post-Authorization Safety Study of the Use of Intravenous Telavancin (VIBATIV®) in the Clinical Setting (Telavancin PASS)
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Isle of Man
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS9669
First published:
06/05/2015
Study
Planned
Questioner to cancer patients MSC-INHP-QCP1 (Questioner to cancer patients, Study MSC-INHP-8800)
Hungary
Poland
Switzerland
Türkiye
United Kingdom
EU PAS number:
EUPAS8800
First published:
22/04/2015
Study
Ongoing
UCL School of Pharmacy, University College London
United Kingdom
First published:
21/04/2015
Institution
Outdated
Educational Institution
ENCePP partner
Comparative Effectiveness of Oral Anticoagulants: A Cohort Study
United States
EU PAS number:
EUPAS3061
First published:
14/04/2015
Study
Finalised
Severe Gout Registry (SGR)
Netherlands
EU PAS number:
EUPAS9073
First published:
08/04/2015
Study
Planned
Comparison of continuous local anaesthetic and systemic pain treatment after axillary lymphadenectomy in breast carcinoma patients - a prospective randomized study. (CCLAA)
Slovenia
EU PAS number:
EUPAS9209
First published:
06/04/2015
Study
Finalised
Does a continuous local anaesthetic pain treatment after immediate tissue expander reconstruction in breast carcinoma patients more efficiently reduce acute postoperative pain - a prospective randomised study (DCLAE)
Slovenia
EU PAS number:
EUPAS9215
First published:
06/04/2015
Study
Finalised
Long-term outcomes and adverse events of therapy with inhaled corticosteroids, long-acting beta-2-agonists and anticholinergic drugs in hospitalised patients with Chronic Obstructive Pulmonary Disease (COPD) - a cohort study based on health information systems in three Italian regions (OUTPUL)
Italy
EU PAS number:
EUPAS1578
First published:
30/03/2015
Study
Finalised
Evaluation of patients with chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD) who would benefit from aclidinium bromide treatment
United Kingdom
EU PAS number:
EUPAS4902
First published:
25/03/2015
Study
Finalised
A Multinational Retrospective Medical Record Review to Evaluate Utilisation Patterns of ADASUVE® (Staccato loxapine for inhalation) in Agitated Persons in Routine Clinical Care
Austria
France
Germany
Romania
Spain
Sweden
EU PAS number:
EUPAS8419
First published:
24/03/2015
Study
Planned
A description of oral and non-insulin injected hypoglycemic therapy utilization patterns including initiation, switching, and discontinuation (Non-insulin hypoglycemic therapy utilization)
United States
EU PAS number:
EUPAS4373
First published:
23/03/2015
Study
Finalised
The efficacy and safety of biosimilar infliximab CT-P13 in IBD: a prospective, nationwide, observational cohort (Biosimilar infliximab in IBD)
Hungary
EU PAS number:
EUPAS9053
First published:
21/03/2015
Study
Ongoing
Real-life effectiveness evaluation of the long-acting muscarinic antagonist aclidinium bromide (Eklira®) for the management of COPD in a routine UK primary care population - Study 1 (Real-life acceptability of Eklira)
United Kingdom
EU PAS number:
EUPAS6573
First published:
17/03/2015
Study
Finalised
Real-life effectiveness (and cost impact) evaluation of fixed-dose combination fluticasone propionate/formoterol (Flutiform®) for the management of asthma in a routine UK primary care population - Phase 1 (Real-life effectiveness of Flutiform® Phase 1)
United Kingdom
EU PAS number:
EUPAS4872
First published:
17/03/2015
Study
Finalised
Real-life effectiveness (and cost impact) evaluation of fixed-dose combination fluticasone propionate/formoterol (Flutiform®) for the management of asthma in a routine UK primary care population – Phase 2 (Real-life effectiveness of Flutiform - Phase 2)
United Kingdom
EU PAS number:
EUPAS7641
First published:
17/03/2015
Study
Finalised
Lamotrigine use in Pregnancy and Risk of Orofacial Clefts
Belgium
Croatia
Denmark
France
Germany
Ireland
Italy
Malta
Netherlands
Norway
Poland
Spain
Switzerland
United Kingdom
EU PAS number:
EUPAS8615
First published:
16/02/2015
Study
Finalised
Real-world effectiveness of extrafine vesrus standard particle inhaled corticosteroids: A comparative effectiveness analysis of extrafine (EF) hydrofluoroalkane beclometasone (HFA-BDP) and Ciclesonide versus commonly prescribed standard particle inhaled corticosteroids for patients prescribed asthma therapy in The Netherlands (Extrafine vesrus stand particle ICS effectiveness)
Netherlands
EU PAS number:
EUPAS8391
First published:
21/01/2015
Study
Finalised
Evaluation of a regional information campaign on the appropriate use of antibiotics: a prospective controlled study
Italy
EU PAS number:
EUPAS7901
First published:
19/12/2014
Study
Ongoing
Emergency contraception. A safety and drug utilitation study in Spain
Spain
EU PAS number:
EUPAS2860
First published:
30/11/2014
Study
Ongoing
Compare data sources
Compare data sources